secwatch.observer — SEC 8-K summary
======================================

Issuer:     CERO THERAPEUTICS HOLDINGS, INC. (CERO)
CIK:        0001870404
Form:       8-K
Filed at:   2024-09-25T23:59:59+00:00
Accession:  0001213900-24-081792
Event type: leadership
Sentiment:  negative
Materiality: 0.75
Item codes: 1.01, 3.02, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CERo raises $1.2M, CEO and CTO resign; CER-1236 on clinical hold
----------------------------------------------------------------

- CEO Brian Atwood resigns effective no later than Sep 30, 2024; CTO Daniel Corey resigns immediately.
- Chris Ehrlich appointed interim Chairman and CEO; board searching for permanent replacement.
- Raised ~$1.2M via private placement of Series C preferred stock and warrants at $1,000/share.
- CER-1236 remains on clinical hold; Type A meeting with FDA requested to address two questions.
- CFO Charles Carter also stepping down; cost reductions being implemented.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1870404/000121390024081792/0001213900-24-081792-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1870404/000121390024081792/ea0215346-8k_cerothera.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-081792

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer